Benjamin Planquette
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Benjamin Planquette has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
G. Meyer
5 shared publicationsO. Sanchez
4 shared publications- Olivier Sanchez
Paris Cité University, Paris, France
4 shared publications D. Maurice
Service de pneumologie et de soins intensifs, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France
2 shared publicationsG. Mourin
2 shared publicationsGuy Meyer
Department of Respiratory and Intensive Care, Université Paris Descartes, AP-HP, Paris, France
2 shared publications
Latest Publications
- 1 January 2017
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 34, A185-A186
Monitorage de la pCO2 par voie transcutanée après chirurgie thoracique : étude de faisabilité
- 1 January 2017
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 34, A185-A186
Monitorage de la pCO2 par voie transcutanée après chirurgie thoracique : étude de faisabilité
- 20 October 2015
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 17 (12) , 1-7
Fibrinolysis for Acute Care of Pulmonary Embolism in the Intermediate Risk Patient
Controversy over the role of fibrinolysis in patients with intermediate-risk pulmonary embolism (PE) has persisted because of the lack of adequately sized trials. The PEITHO study now allows a more precise estimate of the risk to benefit ratio of fibrinolysis in these patients. This trial enrolled patients with intermediate-risk PE who were randomized to receive heparin with either tenecteplase or placebo. Fibrinolysis was associated with a significant reduction in the combined end-point of death or hemodynamic decompensation, but also with a significant increase in the risk of major bleeding. The primary efficacy end-point occurred in 2.6 % of the patients in the tenecteplase group and in 5.6 % of the patients in the placebo group (OR, 0.44; 95 % CI, 0.23 to 0.87), conversely, major extracranial bleeding occurred in 6.3 % and 1.2 % in the tenecteplase and placebo groups, respectively (OR, 5.55; 95 % CI, 2.3 to 13.39) and stroke occurred in 2.4 % and in 0.2 % of the patients in the tenecteplase group and in the placebo group, respectively (OR, 12.10; 95 % CI, 1.57 to 93.39). No difference was observed for the risk of death alone and the risk of full-dose thrombolytic therapy outweighs its benefit in patients with intermediate-risk PE. Recent meta-analyses suggest that fibrinolysis may be associated with a slight reduction in overall mortality offset by an increase in major bleeding. Two pilot studies suggest that a reduced dose of fibrinolysis may produce significant hemodynamic improvement with a low risk of major bleeding. These options need to be evaluated in larger studies including patients with a higher risk of adverse outcome than those included in the PEITHO study.
- 20 October 2015
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 17 (12) , 1-7
Fibrinolysis for Acute Care of Pulmonary Embolism in the Intermediate Risk Patient
Controversy over the role of fibrinolysis in patients with intermediate-risk pulmonary embolism (PE) has persisted because of the lack of adequately sized trials. The PEITHO study now allows a more precise estimate of the risk to benefit ratio of fibrinolysis in these patients. This trial enrolled patients with intermediate-risk PE who were randomized to receive heparin with either tenecteplase or placebo. Fibrinolysis was associated with a significant reduction in the combined end-point of death or hemodynamic decompensation, but also with a significant increase in the risk of major bleeding. The primary efficacy end-point occurred in 2.6 % of the patients in the tenecteplase group and in 5.6 % of the patients in the placebo group (OR, 0.44; 95 % CI, 0.23 to 0.87), conversely, major extracranial bleeding occurred in 6.3 % and 1.2 % in the tenecteplase and placebo groups, respectively (OR, 5.55; 95 % CI, 2.3 to 13.39) and stroke occurred in 2.4 % and in 0.2 % of the patients in the tenecteplase group and in the placebo group, respectively (OR, 12.10; 95 % CI, 1.57 to 93.39). No difference was observed for the risk of death alone and the risk of full-dose thrombolytic therapy outweighs its benefit in patients with intermediate-risk PE. Recent meta-analyses suggest that fibrinolysis may be associated with a slight reduction in overall mortality offset by an increase in major bleeding. Two pilot studies suggest that a reduced dose of fibrinolysis may produce significant hemodynamic improvement with a low risk of major bleeding. These options need to be evaluated in larger studies including patients with a higher risk of adverse outcome than those included in the PEITHO study.
- 1 January 2015
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 32, A177
Connaissance de l’algorithme diagnostique de l’embolie pulmonaire en médecine générale
- 1 January 2015
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 32, A177
Connaissance de l’algorithme diagnostique de l’embolie pulmonaire en médecine générale
- 1 January 2015
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 26 (1) , 18-22
Knowledge of the diagnostic algorithm for pulmonary embolism in primary care
- 1 January 2015
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 26 (1) , 18-22
Knowledge of the diagnostic algorithm for pulmonary embolism in primary care
- Open Access
- 18 September 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (6) , 1082-1084
An unusual cause of pulmonary artery pseudoaneurysm: acrylate embolism
Sclerotherapy is commonly used to manage bleeding from oesophageal varices. In a patient with cirrhosis of the liver, sclerotherapy with bucrylate was followed by a pulmonary embolism and then by a decline in general health. A chest radiograph taken 5 months later disclosed a left perihilar opacity, surrounding and invading the pulmonary artery. Despite moderate fixation by positron emission tomography and inconclusive bronchoscopy findings, an upper left lobectomy was deemed in order. A left pulmonary artery pseudoaneurysm was found during the surgery. The pseudoaneurysm ruptured during dissection, requiring a left pneumonectomy. The pathological examination showed shredding of the left pulmonary artery, which contained foreign material. At points of contact with this material, destruction and severe polymorphic inflammation of the pulmonary parenchyma were noted. There was no evidence of tumour or infection. These findings strongly suggested an iatrogenic pulmonary artery pseudoaneurysm related to a bucrylate embolism through porto-systemic vascular shunts. We are not aware of previously reported cases.
- 18 September 2012
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 15 (6) , 1082-1084
Open AccessAn unusual cause of pulmonary artery pseudoaneurysm: acrylate embolism
Sclerotherapy is commonly used to manage bleeding from oesophageal varices. In a patient with cirrhosis of the liver, sclerotherapy with bucrylate was followed by a pulmonary embolism and then by a decline in general health. A chest radiograph taken 5 months later disclosed a left perihilar opacity, surrounding and invading the pulmonary artery. Despite moderate fixation by positron emission tomography and inconclusive bronchoscopy findings, an upper left lobectomy was deemed in order. A left pulmonary artery pseudoaneurysm was found during the surgery. The pseudoaneurysm ruptured during dissection, requiring a left pneumonectomy. The pathological examination showed shredding of the left pulmonary artery, which contained foreign material. At points of contact with this material, destruction and severe polymorphic inflammation of the pulmonary parenchyma were noted. There was no evidence of tumour or infection. These findings strongly suggested an iatrogenic pulmonary artery pseudoaneurysm related to a bucrylate embolism through porto-systemic vascular shunts. We are not aware of previously reported cases.
- Open Access
- 18 December 2011
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 14 (3) , 244-248
Early respiratory acidosis is a new risk factor for pneumonia after lung resection
Postoperative pneumonia (POP) is a life-threatening complication of lung resection (LR). Its risk factors, bacteriological profile and outcome are not well known. The aims of this study were to describe the outcome and causal bacteria and to identify risk factors for POP. We reviewed all cases admitted to intensive care after LR. Clinical parameters, operative and postoperative data were recorded. POP was suspected on the basis of fever, radiographic infiltrate, and either leucocytosis or purulent sputum. The diagnosis was confirmed by culture of a respiratory sample. Risk factors for POP were identified by univariate and multivariate analysis. We included 159 patients in this study. POP was diagnosed in 23 patients (14.4%) and was associated with a higher hospital mortality rate (30% versus 5%, P = 0.0007) and a longer hospital stay. Members of the Enterobacteriaceae and Pseudomonas species were the most frequently identified pathogens. Early respiratory acidosis (ERA; OR, 2.94; 95% CI, 1.1–8.1), blood transfusion (OR, 3.8; 95% CI, 1.1–13.1), bilobectomy (OR, 7.26; 95% CI, 1.2–43.1) and smoking history (OR, 1.84; 95% CI, 1.1–3) were identified as independent risk factors. ERA may be a risk factor for POP and could serve as a target for therapeutic interventions.
- 18 December 2011
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 14 (3) , 244-248
Open AccessEarly respiratory acidosis is a new risk factor for pneumonia after lung resection
Postoperative pneumonia (POP) is a life-threatening complication of lung resection (LR). Its risk factors, bacteriological profile and outcome are not well known. The aims of this study were to describe the outcome and causal bacteria and to identify risk factors for POP. We reviewed all cases admitted to intensive care after LR. Clinical parameters, operative and postoperative data were recorded. POP was suspected on the basis of fever, radiographic infiltrate, and either leucocytosis or purulent sputum. The diagnosis was confirmed by culture of a respiratory sample. Risk factors for POP were identified by univariate and multivariate analysis. We included 159 patients in this study. POP was diagnosed in 23 patients (14.4%) and was associated with a higher hospital mortality rate (30% versus 5%, P = 0.0007) and a longer hospital stay. Members of the Enterobacteriaceae and Pseudomonas species were the most frequently identified pathogens. Early respiratory acidosis (ERA; OR, 2.94; 95% CI, 1.1–8.1), blood transfusion (OR, 3.8; 95% CI, 1.1–13.1), bilobectomy (OR, 7.26; 95% CI, 1.2–43.1) and smoking history (OR, 1.84; 95% CI, 1.1–3) were identified as independent risk factors. ERA may be a risk factor for POP and could serve as a target for therapeutic interventions.
- 30 June 2011
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 28 (6) , 778-789
Prise en charge diagnostique et thérapeutique de l’embolie pulmonaire grave
- 30 June 2011
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 28 (6) , 778-789
Prise en charge diagnostique et thérapeutique de l’embolie pulmonaire grave